Nanoscope Therapeutics Appoints Ademola Daramola as Vice President, Quality and Compliance

PRIVATEMar 20, 2025

Position

Vice President

Company

Nanoscope Therapeutics

Ademola Daramola

adaramola@nanostherapeutics.com

DallasBiotechnologyHealth CareMedicalTherapeutics

Description

Nanoscope Therapeutics announced the appointment of Ademola Daramola, D.Sc., as Vice President, Quality and Compliance. Dr. Daramola brings over two decades of experience in developing processes and managing workflows for quality assurance, compliance, and operational excellence in the pharmaceutical and medical device industries.

Other recent leadership changes in Medical and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Igor Matushansky, MD, PhD, Joins Immuneering as Chief Medical Officer (March 20, 2025)
Bristol Myers Squibb Appoints Osama Braiwish as General Manager for Saudi Arabia and Gulf Countries (March 20, 2025)
Acrivon Therapeutics Appoints Adam Levy, Ph.D., M.B.A. as Chief Financial Officer (March 14, 2025)
Life Seal Vascular Appoints Matt Thompson as Chief Executive Officer (CEO) (March 13, 2025)
Imugene Appoints Darren Keamy as Chief Financial Officer and Company Secretary (March 4, 2025)
Qnovia Appoints Mario Danek as President and CEO; James Watson as COO (April 10, 2025)

Who to call at Nanoscope Therapeutics, and when

A new leader at Nanoscope Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.

An alert the day Nanoscope Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Nanoscope Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Nanoscope Therapeutics. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Nanoscope Therapeutics

Location

1312 BROWN TRAIL

Dallas, Texas, United States

About

Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial, also in the first half of 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Nanoscope Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans